↓ Skip to main content

Dove Medical Press

Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome

Overview of attention for article published in Therapeutics and Clinical Risk Management, September 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 X users
facebook
1 Facebook page

Readers on

mendeley
45 Mendeley
Title
Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome
Published in
Therapeutics and Clinical Risk Management, September 2015
DOI 10.2147/tcrm.s89737
Pubmed ID
Authors

Young-Mo Yang, Eun Joo Choi

Abstract

Polycystic ovary syndrome (PCOS) is an endocrinopathy that affects approximately 10% of reproductive-aged women throughout their lives. Women with PCOS present with heterogeneous symptoms including ovulatory dysfunction, hyperandrogenism, and polycystic ovaries. Therefore, lifelong individualized management should be considered. Pharmacological agents commonly used to manage the symptoms are metformin and oral contraceptive pills. Although these medications have been beneficial in treating PCOS symptoms, their efficacy and safety are still not entirely elucidated. This study aimed to report the efficacy and safety of metformin, oral contraceptives, or their combination in the treatment of PCOS and to define their specific individual roles. A literature search of original studies published in PubMed and Scopus was conducted to identify studies comparing metformin with oral contraceptives or evaluating the combination of both in PCOS. Eight clinical trials involving 313 patients were examined in the review. The intervention dosage of metformin ranged from 1,000 to 2,000 mg/d and that of oral contraceptives was ethinylestradiol 35 µg and cyproterone acetate 2 mg. Lower body mass index was observed with regimens including metformin, but increased body mass index was observed in monotherapy with oral contraceptives. Administration of metformin or oral contraceptives, especially as monotherapy, had a negative effect on lipid profiles. In addition, there are still uncertainties surrounding the effects of metformin or oral contraceptives in the management of insulin level, although they improved total testosterone and sex hormone-binding globulin levels. In the included studies, significant side effects due to metformin or oral contraceptives were not reported. The clinical trials suggest that metformin or oral contraceptives are at least patient convenient, efficacious, and safe for the treatment of PCOS. However, well-designed, prospective, long-term, large-scale, randomized clinical trials are necessary to elucidate the efficacy and safety of metformin, oral contraceptives, or both in the treatment of PCOS, and to elucidate their individual roles in the treatment of this condition.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 45 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 13%
Student > Bachelor 6 13%
Student > Doctoral Student 5 11%
Student > Ph. D. Student 5 11%
Researcher 4 9%
Other 5 11%
Unknown 14 31%
Readers by discipline Count As %
Medicine and Dentistry 17 38%
Agricultural and Biological Sciences 2 4%
Biochemistry, Genetics and Molecular Biology 2 4%
Nursing and Health Professions 2 4%
Business, Management and Accounting 1 2%
Other 6 13%
Unknown 15 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2015.
All research outputs
#16,862,842
of 25,576,275 outputs
Outputs from Therapeutics and Clinical Risk Management
#808
of 1,324 outputs
Outputs of similar age
#157,381
of 277,197 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#46
of 62 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,324 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,197 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.